纤维肉瘤起源于成纤维细胞，是一种可在所有性别和年龄组中出现的恶性肿瘤。融合基因在人类癌症中尤其普遍，特别是在纤维肉瘤亚型中，它们在肿瘤发生中发挥着巨大的驱动力。许多融合基因是引发这种疾病的致病机制的基础。此外，融合基因类型谱与纤维肉瘤的表型表达之间存在密切关联，使得融合基因不仅可以作为纤维肉瘤有希望的诊断指标，而且可以作为其亚分类的关键基础。同时，越来越多的融合基因编码的嵌合蛋白已被证实可以作为治疗纤维肉瘤的特异性靶标，从而显着提高患者的预后。该综述全面阐述了纤维肉瘤中融合基因形成的机制、融合基因的谱系、检测纤维肉瘤内融合基因的方法以及纤维肉瘤域内融合基因驱动的靶向治疗干预的前景。版权所有 © 2023 Tang, Hu 、文和敏。

Fibrosarcoma, originating from fibroblast cells, represents a malignant neoplasm that can manifest across all genders and age groups. Fusion genes are notably prevalent within the landscape of human cancers, particularly within the subtypes of fibrosarcoma, where they exert substantial driving forces in tumorigenesis. Many fusion genes underlie the pathogenic mechanisms triggering the onset of this disease. Moreover, a close association emerges between the spectrum of fusion gene types and the phenotypic expression of fibrosarcoma, endowing fusion genes not only as promising diagnostic indicators for fibrosarcoma but also as pivotal foundations for its subcategorization. Concurrently, an increasing number of chimeric proteins encoded by fusion genes have been substantiated as specific targets for treating fibrosarcoma, consequently significantly enhancing patient prognoses. This review comprehensively delineates the mechanisms behind fusion gene formation in fibrosarcoma, the lineage of fusion genes, methodologies employed in detecting fusion genes within fibrosarcoma, and the prospects of targeted therapeutic interventions driven by fusion genes within the fibrosarcoma domain.Copyright © 2023 Tang, Hu, Wen and Min.